Recipient of the 2017 Life Science Leadership Award to be presented at the Closing Lunch
View Full Press Release Here
Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past two decades the firm has managed $450 million in capital and invested in more than 70 life science companies through its flagship Pappas Ventures business unit as well as its Specialized Fund Management business unit.
Art currently serves as a director for CoLucid Pharmaceuticals (NASDAQ: CLCD), for which he is Chairman and also served as the founding CEO, and Aura Biosciences. He also serves as a board observer for Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN now NYSE: Q), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Plexxikon, which was sold to Daiichi Sankyo in 2011.
Art is a member of the Board of Directors of the National Venture Capital Association and the North Carolina Biotechnology Center, where he was a past chair. He is also a member of the Board of Directors of the Medical University of South Carolina Foundation for Research Development, the Board of Trustees of The Wistar Institute, a National Cancer Institute center, the Board of Advisors of the Duke Cancer Institute, the Advisory Board of the BioExec Institute, the CEO Roundtable on Cancer, and BayHelix, an organization of global life science community leaders. He also oversees the Catalyst Fund with Wake Forest Innovations. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center.
Art has a clear passion for developing and mentoring entrepreneurs and helping them build great companies. His relationships are broad and deep and he nurtures them as he does his family and friends.
Ohio State University (BS in Biology)
Xavier University (MBA in Finance)
See Art accept the Life Science Leadership Award at CED Life Science Conference 2017